IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Farina, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.854
AS - Asia 3.184
EU - Europa 2.216
SA - Sud America 592
AF - Africa 96
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.960
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.719
SG - Singapore 1.420
IT - Italia 797
CN - Cina 738
BR - Brasile 484
HK - Hong Kong 319
DE - Germania 307
VN - Vietnam 243
FR - Francia 197
FI - Finlandia 187
GB - Regno Unito 132
UA - Ucraina 121
RU - Federazione Russa 109
TR - Turchia 100
IN - India 89
CA - Canada 66
BD - Bangladesh 54
IE - Irlanda 51
PL - Polonia 51
NL - Olanda 42
SE - Svezia 42
ZA - Sudafrica 42
MX - Messico 41
CZ - Repubblica Ceca 39
JP - Giappone 38
AR - Argentina 36
IQ - Iraq 36
AT - Austria 31
ES - Italia 29
BE - Belgio 18
EC - Ecuador 18
ID - Indonesia 17
AU - Australia 16
SA - Arabia Saudita 14
CO - Colombia 13
EG - Egitto 13
UZ - Uzbekistan 12
MA - Marocco 11
VE - Venezuela 11
TH - Thailandia 10
PY - Paraguay 9
JO - Giordania 8
KR - Corea 8
LT - Lituania 8
PE - Perù 8
CR - Costa Rica 7
GR - Grecia 7
IL - Israele 7
KG - Kirghizistan 7
OM - Oman 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
PA - Panama 6
PS - Palestinian Territory 6
PT - Portogallo 6
CH - Svizzera 5
CL - Cile 5
ET - Etiopia 5
IR - Iran 5
KE - Kenya 5
KZ - Kazakistan 5
MY - Malesia 5
RO - Romania 5
SN - Senegal 5
TW - Taiwan 5
UY - Uruguay 5
AL - Albania 4
DK - Danimarca 4
LK - Sri Lanka 4
LV - Lettonia 4
NP - Nepal 4
PH - Filippine 4
TN - Tunisia 4
AZ - Azerbaigian 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
JM - Giamaica 3
LB - Libano 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
GT - Guatemala 2
HU - Ungheria 2
MD - Moldavia 2
NO - Norvegia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
IM - Isola di Man 1
LA - Repubblica Popolare Democratica del Laos 1
MS - Montserrat 1
MT - Malta 1
Totale 9.949
Salva come PNG Salva come JPEG
Città #
Singapore 795
Ashburn 465
San Jose 369
Hong Kong 316
New York 192
Fairfield 180
Beijing 170
The Dalles 162
Munich 161
Dallas 157
Los Angeles 138
Brescia 123
Chandler 118
Helsinki 117
Lauterbourg 97
Woodbridge 91
Seattle 84
Milan 83
Wilmington 80
Ho Chi Minh City 78
Jacksonville 77
Houston 75
Des Moines 74
Princeton 68
Istanbul 67
Hanoi 56
São Paulo 56
Council Bluffs 55
Santa Clara 51
Shanghai 50
Turku 50
Boardman 49
Cambridge 47
Dublin 46
Redondo Beach 44
Rome 44
San Francisco 44
Chicago 42
Moscow 40
Buffalo 36
Warsaw 36
Orem 35
Tokyo 34
Frankfurt am Main 33
Ann Arbor 32
London 32
Brno 26
Denver 25
Johannesburg 25
Brooklyn 23
Montreal 23
Nuremberg 23
Romola 19
Stockholm 19
Toronto 19
Mexico City 18
Atlanta 17
Chennai 17
Poplar 17
Turin 17
Boston 16
Lappeenranta 16
Paris 16
Pune 16
Manchester 15
Phoenix 15
Tianjin 14
Da Nang 13
Nanchang 13
Nanjing 13
San Diego 13
Wroclaw 13
Barlassina 12
Charlotte 12
Vienna 12
Amsterdam 11
Baghdad 11
Brussels 11
Florence 11
Rio de Janeiro 11
Tashkent 11
Verona 11
Belo Horizonte 10
Biên Hòa 10
Bologna 10
Brasília 10
Mumbai 10
Dearborn 9
Düsseldorf 9
Jinan 9
Olomouc 9
Amman 8
Bergamo 8
Buenos Aires 8
Curitiba 8
Genoa 8
Haiphong 8
Philadelphia 8
Porto Alegre 8
Bishkek 7
Totale 5.980
Salva come PNG Salva come JPEG
Nome #
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors and Circulating Endothelial Cells in Patients With Primary Myelofibrosis 225
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 203
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 177
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 172
Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma 168
Advances in CMV Management: A Single Center Real-Life Experience 167
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 161
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 159
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 157
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 152
Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia 149
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 148
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 147
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 143
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 138
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 137
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 137
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 132
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 129
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 128
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 125
Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk 125
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 124
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 123
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 120
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 120
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 119
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 119
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 119
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 118
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 117
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 115
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 114
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 111
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 110
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 109
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 108
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 107
Nutritional strategies to improve VRE control 107
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 103
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors 103
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 103
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 99
dsDNA from extracellular vesicles (EVs) in adult AML 99
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 98
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 98
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 96
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 96
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 96
Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis 95
POST REMISSION SEQUENTIAL MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 Q-PCR AND MULTIPARAMETRIC FLOW CYTOMETRY PREDICTS RELAPSE AND MAY HELP TO ADDRESS THE RISK ADAPTED THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS 94
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 92
Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant 92
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 91
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 90
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 90
Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study 87
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 87
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 86
In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration 85
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 82
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 80
Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These “Magic Bullets” 79
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia 77
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 77
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 75
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 74
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis 73
Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients 72
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 72
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) 71
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 71
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study 71
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient 71
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 69
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms 66
Impact of transforming growth factor-β2 enriched food for special medical purposes on nutritional status, microbiota and clinical outcomes after allogeneic hematopoietic stem cell transplantation: prospective analysis of 192 consecutive patients 64
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 63
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors 63
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? 62
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 61
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis 61
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 60
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 58
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS 57
Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study 57
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles 56
A case of Severe Gastrointestinal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation: Can We Improve the Evaluation of the “Gut Fitness”? 55
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 54
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 54
Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study 54
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study 53
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 53
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient 53
The possible role of mutated endothelial cells in myeloproliferative neoplasms 51
Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance? 49
Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50 47
Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report 43
Letter in response to "Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: a Delphi Consensus" 43
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? 41
Totale 9.811
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021149 0 0 0 0 0 0 0 0 0 84 34 31
2021/2022354 22 15 11 44 13 18 19 39 22 48 22 81
2022/2023445 45 12 17 41 33 88 2 53 55 11 36 52
2023/2024808 31 21 57 52 59 154 43 45 133 27 24 162
2024/20252.506 27 60 57 246 178 181 175 123 400 238 478 343
2025/20265.106 405 549 395 734 587 455 846 308 383 444 0 0
Totale 10.118